| Synonyms: | |
| Status: | Phase 3 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | O3571H3R8N |
| InChI Key | JNGVJMBLXIUVRD-SFHVURJKSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C19H14F3N3O3 |
| Molecular Weight | 389.33 |
| AlogP | 3.22 |
| Hydrogen Bond Acceptor | 5.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 5.0 |
| Polar Surface Area | 106.14 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 28.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| MODULATOR | Androgen Receptor modulator |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Transferase
|
- | - | - | - | 5.495 | |
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIb
|
- | - | - | - | 1.45-18.84 | |
|
Transcription factor
Nuclear receptor
Nuclear hormone receptor subfamily 3
Nuclear hormone receptor subfamily 3 group C
Nuclear hormone receptor subfamily 3 group C member 4
|
- | 3-20 | - | 0.55-38 | -25-90 |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | 3 | D002289 | ClinicalTrials |
| Muscular Atrophy | 3 | D009133 | ClinicalTrials |
| Breast Neoplasms | 3 | D001943 | ClinicalTrials |
| Cachexia | 2 | D002100 | ClinicalTrials |
| Triple Negative Breast Neoplasms | 2 | D064726 | ClinicalTrials |
| Urinary Incontinence, Stress | 2 | D014550 | ClinicalTrials |
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL1738889 |
| DrugBank | DB12078 |
| EPA CompTox | DTXSID30233006 |
| FDA SRS | O3571H3R8N |
| PDB | RLJ |
| SureChEMBL | SCHEMBL109069 |
| ZINC | ZINC000035793636 |